S Peter Kang

Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Lon Smith, Omar Laterza, Robert H Pierce, 2015, Clinical Cancer Research.

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Antoni Ribas, Caroline Robert, Anthony M Joshua, 2013, The New England journal of medicine.

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Antoni Ribas, Caroline Robert, Anthony M Joshua, 2014, The Lancet.

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

Wei Zhou, Dirk Schadendorf, Reinhard Dummer, 2015, The Lancet. Oncology.